Probatebeta
Target

PCSK9

Proprotein convertase subtilisin/kexin type 9

As of the edition of 20 October 2026, PCSK9 (proprotein convertase subtilisin/kexin type 9, UniProt Q8NBP7) has 22 drugs tested at it and 19 companies on the list, 4 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q8NBP7
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
66
Disease areas
Nutrition and metabolism; Heart and blood vessels; Inherited and neonatal; Nervous system; Cancer; Urinary and reproductive; Lungs and airways; Pregnancy and women's health
Registered trials of its drugs
371

Drugs at this target

StatusCount
Marketed5
Active8
Went quiet3
Stopped4
Status not established2
Total22
DrugStatusFurthest phaseUS protection
EvolocumabMarketedPhase 4Ends 2028
AlirocumabMarketedPhase 4Ends 2028
InclisiranMarketedPhase 4none listed
BococizumabStoppedPhase 3none listed
RecaticimabActivePhase 4none listed
TafolecimabActivePhase 4none listed
Inclisiran sodiumMarketedPhase 4Ends 2034
AZD0780ActivePhase 3none listed
LerodalcibepMarketedPhase 3Ends 2037
OngericimabActivePhase 3none listed
AK102ActivePhase 3none listed
AZD8233StoppedPhase 2none listed

12 of 22 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A4
Route B5
Engaged8
Undetermined2
Total on the list19
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute A
AmgenRoute B
LIB TherapeuticsRoute B

The other 16 companies at PCSK9

In the product

19 companies in all; 16 are not named here, and no score is.

See the 19 companies at PCSK9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PCSK9

Other targets in nutrition and metabolism

Companies holding approvals at PCSK9